Viking Therapeutics VK2735 Phase 3 trial

Latest Post

Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth Laurus Labs to Acquire 60% Stake in Canadian Biotech Firm Galenvs Sciences for $3.75 Million Fortis Healthcare Acquires Suguna Hospital in Bengaluru for ₹277 Crore Ro Launches Robin AI Health Agent to Personalise Medication and Patient Care Recommendations Laurus Labs Q2 Results: Net Profit Surges 126% to ₹441 Crore as Revenue Grows 33%

Viking Therapeutics VK2735 Phase 3 Trial: Bold Oral Gamble

October 14, 2026 Simone Lamb

Viking Therapeutics VK2735 Phase 3 trial: two 68-week SUNRISE studies of oral VK2735 will enrol about 560 adults each. The drug is still investigational.

You missed

Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth

October 30, 2026 Simone Lamb

Laurus Labs to Acquire 60% Stake in Canadian Biotech Firm Galenvs Sciences for $3.75 Million

October 30, 2026 Simone Lamb

Healthcare Services

Fortis Healthcare Acquires Suguna Hospital in Bengaluru for ₹277 Crore

October 30, 2026 Simone Lamb

Ro Launches Robin AI Health Agent to Personalise Medication and Patient Care Recommendations

October 30, 2026 Simone Lamb